PDT Partners LLC Acquires Shares of 68,292 Bruker Corporation $BRKR

PDT Partners LLC acquired a new stake in Bruker Corporation (NASDAQ:BRKR) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 68,292 shares of the medical research company’s stock, valued at approximately $4,110,000.

A number of other hedge funds have also recently modified their holdings of BRKR. Los Angeles Capital Management LLC acquired a new stake in Bruker during the fourth quarter worth about $26,000. Allworth Financial LP lifted its holdings in Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares during the period. Essential Partners LLC acquired a new position in Bruker in the first quarter valued at approximately $36,000. Global Retirement Partners LLC purchased a new stake in Bruker in the 2nd quarter worth approximately $38,000. Finally, Parallel Advisors LLC boosted its position in Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on BRKR. Wall Street Zen raised shares of Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. UBS Group set a $60.00 price target on shares of Bruker in a report on Wednesday, June 24th. Wolfe Research assumed coverage on shares of Bruker in a research report on Monday, June 1st. They set a “peer perform” rating on the stock. Guggenheim lifted their price objective on shares of Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, TD Cowen reiterated a “hold” rating on shares of Bruker in a research report on Wednesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $56.64.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $56.85 on Wednesday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. The firm has a fifty day moving average of $58.69 and a 200 day moving average of $47.71. The firm has a market cap of $8.66 billion, a PE ratio of -81.21, a PEG ratio of 1.74 and a beta of 1.28. Bruker Corporation has a one year low of $28.53 and a one year high of $65.30.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The business had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. During the same period last year, the firm posted $0.32 earnings per share. The company’s revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts predict that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s dividend payout ratio (DPR) is currently -28.57%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.